The use of GLP-1 agonists such as Wegovy, Ozempic, and Mounjaro is rapidly rising in Australia, but their high costs are fueling debate over whether the government should subsidize them through the Pharmaceutical Benefits Scheme (PBS). Currently, patients pay around $395–$460 per month, making the drugs unaffordable for many.
Supporters argue that obesity is a chronic disease like diabetes or hypertension and deserves funded treatment. “The people who need them the most are the ones who can least afford them,” said Dr. Terri-Lynne South of the RACGP, noting that obesity is more common in lower-income communities. Advocates stress that the medications work best when paired with lifestyle and multidisciplinary care.
Others, however, caution against overreliance. Critics such as nutrition expert Dr. Emma Beckett warn the drugs may worsen diet culture, cause malnutrition if misused, and create stigma for those who cannot access them.
With two-thirds of Australian adults overweight or obese, experts agree that the epidemic requires urgent action — but differ on whether subsidizing these drugs is the right solution.
